• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

欧洲利益相关者对患者参与卫生技术评估(HTA)的现状及潜在障碍的看法。

Stakeholder perspectives on the current status and potential barriers of patient involvement in health technology assessment (HTA) across Europe.

作者信息

Holtorf Anke-Peggy, Bertelsen Neil, Jarke Hannes, Dutarte Maria, Scalabrini Silvia, Strammiello Valentina

机构信息

Health Outcomes Strategies GmbH, Basel, Switzerland.

College of Pharmacy, University of Utah, Salt Lake City, UT, USA.

出版信息

Int J Technol Assess Health Care. 2024 Dec 19;40(1):e81. doi: 10.1017/S0266462324004707.

DOI:10.1017/S0266462324004707
PMID:39698996
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11703633/
Abstract

BACKGROUND

There are wide variations in the practices of patient involvement in health technology assessment (HTA) in Europe. The field is lacking a consensus on good practices, leading to divergent processes, methods, and evaluation of patient involvement. To identify potential good practice approaches and current gaps, a structured online survey was conducted among HTA stakeholders, including HTA practitioners, patient stakeholders, industry representatives, and others who had experienced patient involvement in HTA.

METHODS

The questionnaire was co-created by HTA experts, patient stakeholders, and industry representatives and disseminated between 29 April and 14 September 2022.

RESULTS

Responses (n = 168) were submitted from thirty-two European countries by HTA practitioners (n = 33), patient stakeholders (n = 75), industry stakeholders (n = 42), providers (n = 5), academics (n = 7), and others (n = 6). The responses indicated that "is the principle rationale for conducting HTA. In terms of the importance of patient involvement, there was consensus across stakeholder groups that "" and that patient involvement is important "". Shortcomings were identified in the lack of systematic and transparent processes, an unsatisfactory level of information and guidance, and minimal communication and collaboration.

CONCLUSIONS

The diverse stakeholders who responded highlighted the need for improving specific aspects of patient involvement practices, including better guidance and information, a more consistent flow of communication between the HTA body and participating patient stakeholders, and the need to develop and implement a consensus on good practices.

摘要

背景

在欧洲,患者参与卫生技术评估(HTA)的实践存在很大差异。该领域在良好实践方面缺乏共识,导致患者参与的流程、方法和评估各不相同。为了确定潜在的良好实践方法和当前存在的差距,我们对HTA利益相关者进行了一项结构化在线调查,这些利益相关者包括HTA从业者、患者利益相关者、行业代表以及其他有患者参与HTA经验的人。

方法

该问卷由HTA专家、患者利益相关者和行业代表共同创建,并于2022年4月29日至9月14日期间进行了分发。

结果

来自32个欧洲国家的HTA从业者(n = 33)、患者利益相关者(n = 75)、行业利益相关者(n = 42)、提供者(n = 5)、学者(n = 7)和其他人员(n = 6)提交了回复(n = 168)。回复表明“是进行HTA的主要理由。在患者参与的重要性方面,各利益相关者群体达成了共识,即‘’且患者参与很重要”。调查发现了一些不足之处,包括缺乏系统和透明的流程、信息和指导水平不尽人意,以及沟通与协作极少。

结论

做出回复的不同利益相关者强调了改进患者参与实践特定方面的必要性,包括提供更好的指导和信息、HTA机构与参与的患者利益相关者之间更一致的沟通流程,以及制定和实施关于良好实践的共识的必要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8826/11703633/61dbc61e6f75/S0266462324004707_fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8826/11703633/3d04dc29924c/S0266462324004707_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8826/11703633/b3c53afdc41e/S0266462324004707_fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8826/11703633/a43ddef1e33f/S0266462324004707_fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8826/11703633/33514bd7da53/S0266462324004707_fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8826/11703633/61dbc61e6f75/S0266462324004707_fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8826/11703633/3d04dc29924c/S0266462324004707_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8826/11703633/b3c53afdc41e/S0266462324004707_fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8826/11703633/a43ddef1e33f/S0266462324004707_fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8826/11703633/33514bd7da53/S0266462324004707_fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8826/11703633/61dbc61e6f75/S0266462324004707_fig5.jpg

相似文献

1
Stakeholder perspectives on the current status and potential barriers of patient involvement in health technology assessment (HTA) across Europe.欧洲利益相关者对患者参与卫生技术评估(HTA)的现状及潜在障碍的看法。
Int J Technol Assess Health Care. 2024 Dec 19;40(1):e81. doi: 10.1017/S0266462324004707.
2
The three-domain impact framework for characterizing impact of patient involvement in health technology assessment.三域影响框架用于描述患者参与卫生技术评估的影响。
Int J Technol Assess Health Care. 2024 Nov 11;40(1):e52. doi: 10.1017/S0266462324000400.
3
Recommendations for patient involvement in health technology assessment in Central and Eastern European countries.在中东欧国家,关于患者参与卫生技术评估的建议。
Front Public Health. 2023 Jul 3;11:1176200. doi: 10.3389/fpubh.2023.1176200. eCollection 2023.
4
Using social media research in health technology assessment: stakeholder perspectives and scoping review.利用社交媒体进行卫生技术评估研究:利益相关者的观点和范围综述。
Int J Technol Assess Health Care. 2023 Sep 21;39(1):e63. doi: 10.1017/S0266462323002593.
5
STAKEHOLDER INVOLVEMENT THROUGHOUT HEALTH TECHNOLOGY ASSESSMENT: AN EXAMPLE FROM PALLIATIVE CARE.利益相关者全程参与卫生技术评估:姑息治疗实例。
Int J Technol Assess Health Care. 2017 Jan;33(5):552-561. doi: 10.1017/S026646231700068X. Epub 2017 Sep 4.
6
Patient Preferences in the Medical Product Life Cycle: What do Stakeholders Think? Semi-Structured Qualitative Interviews in Europe and the USA.患者在医疗产品生命周期中的偏好:利益相关者的想法是什么?欧洲和美国的半结构化定性访谈。
Patient. 2019 Oct;12(5):513-526. doi: 10.1007/s40271-019-00367-w.
7
Exploring the landscape of health technology assessment in Iran: perspectives from stakeholders on needs, demand and supply.探索伊朗卫生技术评估的全貌:利益相关者对需求、需求和供应的看法。
Health Res Policy Syst. 2024 Jan 15;22(1):11. doi: 10.1186/s12961-023-01097-0.
8
STAKEHOLDER INVOLVEMENT IN HEALTH TECHNOLOGY ASSESSMENT AT NATIONAL LEVEL: A STUDY FROM IRAN.国家层面利益相关者参与卫生技术评估:来自伊朗的一项研究
Int J Technol Assess Health Care. 2016 Jan;32(3):181-9. doi: 10.1017/S0266462316000167. Epub 2016 Aug 15.
9
A situational and stakeholder analysis of health technology assessment in Zimbabwe.津巴布韦卫生技术评估的情境和利益相关者分析。
Int J Technol Assess Health Care. 2024 Apr 29;40(1):e27. doi: 10.1017/S0266462324000266.
10
Potential Barriers of Patient Involvement in Health Technology Assessment in Central and Eastern European Countries.中东欧国家中患者参与健康技术评估的潜在障碍。
Front Public Health. 2022 Jul 28;10:922708. doi: 10.3389/fpubh.2022.922708. eCollection 2022.

引用本文的文献

1
Connecting minds and catalyzing collaboration: the interest groups of health technology assessment international.连接思想,促进合作:国际卫生技术评估兴趣小组
Int J Technol Assess Health Care. 2025 Jul 7;41(1):e43. doi: 10.1017/S0266462325100287.
2
Enhancing Patient Engagement in HTA: Using Consensus Research to Overcome PICO Scoping Challenges Under the EU HTAR.提高患者在卫生技术评估中的参与度:利用共识研究克服欧盟卫生技术评估法规下的PICO范围界定挑战
J Mark Access Health Policy. 2025 Jun 2;13(2):27. doi: 10.3390/jmahp13020027. eCollection 2025 Jun.
3
Development of a framework on the incorporation of real-world evidence (RWE) into cancer drug funding decisions in Canada: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration.

本文引用的文献

1
The three-domain impact framework for characterizing impact of patient involvement in health technology assessment.三域影响框架用于描述患者参与卫生技术评估的影响。
Int J Technol Assess Health Care. 2024 Nov 11;40(1):e52. doi: 10.1017/S0266462324000400.
2
Community participation and stakeholder engagement in determining health service coverage: A systematic review and framework synthesis to assess effectiveness.社区参与和利益相关者参与确定卫生服务覆盖范围:系统评价和框架综合评估有效性。
J Glob Health. 2023 May 12;13:04034. doi: 10.7189/jogh.13.04034.
3
A voice to be heard: patient and public involvement in health technology assessment and clinical practice guidelines in Malaysia.
加拿大将真实世界证据(RWE)纳入癌症药物资金决策的框架制定:加拿大癌症药物价值真实世界证据(CanREValue)合作项目
BMJ Open. 2025 May 30;15(5):e096286. doi: 10.1136/bmjopen-2024-096286.
一个需要被听到的声音:马来西亚的卫生技术评估和临床实践指南中的患者和公众参与。
Int J Technol Assess Health Care. 2021 Mar 22;37:e47. doi: 10.1017/S0266462321000118.
4
Patients and public are important stakeholders in health technology assessment but the level of involvement is low - a call to action.患者和公众是卫生技术评估中的重要利益相关者,但他们的参与程度较低——行动呼吁。
Res Involv Engagem. 2021 Jan 5;7(1):1. doi: 10.1186/s40900-020-00248-9.
5
Evaluation of patient involvement strategies in health technology assessment in Spain: the viewpoint of HTA researchers.评价西班牙卫生技术评估中患者参与策略:HTA 研究人员的观点。
Int J Technol Assess Health Care. 2020 Sep 11;37:e25. doi: 10.1017/S0266462320000586.
6
EUPATI Guidance for Patient Involvement in Medicines Research and Development: Health Technology Assessment.欧洲患者参与药物研发指南:卫生技术评估
Front Med (Lausanne). 2018 Sep 6;5:231. doi: 10.3389/fmed.2018.00231. eCollection 2018.
7
EVALUATION OF PATIENT AND PUBLIC INVOLVEMENT INITIATIVES IN HEALTH TECHNOLOGY ASSESSMENT: A SURVEY OF INTERNATIONAL AGENCIES.评估健康技术评估中的患者和公众参与倡议:对国际机构的调查。
Int J Technol Assess Health Care. 2017 Jan;33(6):715-723. doi: 10.1017/S0266462317000976. Epub 2017 Nov 10.
8
WHY PATIENTS SHOULD BE INVOLVED IN HEALTH TECHNOLOGY ASSESSMENT.为什么患者应该参与卫生技术评估。
Int J Technol Assess Health Care. 2017 Jan;33(1):1-4. doi: 10.1017/S0266462317000241. Epub 2017 May 22.
9
Patients' perspectives in health technology assessment: a route to robust evidence and fair deliberation.患者在健康技术评估中的观点:获得稳健证据和公平审议的途径。
Int J Technol Assess Health Care. 2010 Jul;26(3):334-40. doi: 10.1017/S0266462310000395.
10
"It all depends": conceptualizing public involvement in the context of health technology assessment agencies.“一切都取决于”:在卫生技术评估机构背景下对公众参与的概念化。
Soc Sci Med. 2010 May;70(10):1518-26. doi: 10.1016/j.socscimed.2010.01.036. Epub 2010 Feb 12.